CELL · Bruker Cellular Analysis, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Revenue | $78.59M | $85.39M | $64.30M |
| Cost of Revenue | $24.81M | $28.84M | $19.75M |
| Gross Profit | $53.78M | $56.55M | $44.55M |
| R&D | $53.21M | $58.55M | $47.24M |
| SG&A | $37.71M | $43.40M | $23.20M |
| Total Operating Expenses | $151.84M | $127.34M | $84.95M |
| D&A | $9.00M | $5.60M | $5.10M |
| Operating Income | ($98.05M) | ($70.79M) | ($40.39M) |
| Interest Expense | $910.0K | $1.17M | $1.44M |
| Income Tax | $100.0K | ($55.0K) | $174.0K |
| Net Income | ($98.04M) | ($71.72M) | ($41.58M) |
| EPS - Basic | ($1.42) | ($1.39) | - |
| EPS - Diluted | ($1.42) | ($1.39) | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Cash & Equivalents | $86.52M | $178.10M | $233.41M |
| Accounts Receivable | $18.53M | $25.94M | $12.94M |
| Inventory | $18.86M | $14.55M | $11.05M |
| Accounts Payable | $10.09M | $8.20M | $3.49M |
| Current Assets | $176.95M | $230.57M | $265.57M |
| Total Assets | $226.09M | $287.25M | $299.66M |
| Current Liabilities | $45.49M | $32.75M | $28.97M |
| Long-term Debt | - | - | - |
| Total Liabilities | $84.04M | $79.04M | $54.88M |
| Stockholders' Equity | $142.06M | $208.22M | $23.70M |
| Retained Earnings | ($361.65M) | ($263.61M) | ($191.88M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Operating Cash Flow | ($47.54M) | ($53.13M) | ($35.85M) |
| Investing Cash Flow | ($53.98M) | ($15.82M) | ($3.29M) |
| Financing Cash Flow | $9.68M | $13.64M | $191.52M |
| CapEx | $8.08M | $15.82M | $3.29M |
| Free Cash Flow | ($55.62M) | ($68.95M) | ($39.14M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Profitability | |||
| Gross margin | 68.4% | 66.2% | 69.3% |
| Operating margin | -124.8% | -82.9% | -62.8% |
| EBITDA margin | -113.3% | -76.3% | -54.9% |
| Net margin | -124.7% | -84.0% | -64.7% |
| Free cash flow margin | -70.8% | -80.8% | -60.9% |
| FCF / Net income | 0.57 | 0.96 | 0.94 |
| R&D / Revenue | 67.7% | 68.6% | 73.5% |
| SG&A / Revenue | 48.0% | 50.8% | 36.1% |
| Effective tax rate | - | - | - |
| Return on assets | -43.4% | -25.0% | -13.9% |
| Return on equity | -69.0% | -34.4% | -175.5% |
| Return on invested capital | - | - | - |
| Liquidity | |||
| Current ratio | 3.89 | 7.04 | 9.17 |
| Quick ratio | 3.48 | 6.60 | 8.79 |
| Cash ratio | 1.90 | 5.44 | 8.06 |
| Leverage | |||
| Debt / Equity | - | - | - |
| Debt / Assets | - | - | - |
| Debt / EBITDA | - | - | - |
| Interest coverage | -107.8x | -60.5x | -28.1x |
| Equity multiplier | 1.59 | 1.38 | 12.64 |
| Liabilities / Assets | 0.37 | 0.28 | 0.18 |
| Efficiency | |||
| Asset turnover | 0.35 | 0.30 | 0.21 |
| Inventory turnover | 1.32 | 1.98 | 1.79 |
| Days sales outstanding | 86d | 111d | 73d |
| Days inventory outstanding | 277d | 184d | 204d |
| Days payable outstanding | 148d | 104d | 65d |
| Cash conversion cycle | 215d | 191d | 213d |
| Valuation | |||
| P / E | - | - | - |
| P / B | - | - | - |
| P / S | - | - | - |
| EV / EBITDA | - | - | - |
| Growth | |||
| Revenue growth (YoY) | -8.0% | 32.8% | - |
| Revenue CAGR (3y) | - | - | - |
| Revenue CAGR (5y) | - | - | - |
| Gross profit growth (YoY) | -4.9% | 26.9% | - |
| Operating income growth (YoY) | -38.5% | -75.2% | - |
| Net income growth (YoY) | -36.7% | -72.5% | - |
| EPS growth (YoY) | -2.2% | - | - |
| EPS CAGR (3y) | - | - | - |
| EPS CAGR (5y) | - | - | - |
| FCF growth (YoY) | 19.3% | -76.2% | - |
| FCF CAGR (5y) | - | - | - |
| Book value growth (YoY) | -31.8% | 778.5% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$170.78M totalAntibody Therapeutics$64.32M · 37.7%
Product$56.58M · 33.1%
Service$28.81M · 16.9%
Synthetic Biology$8.96M · 5.2%
Gene Therapy$7.11M · 4.2%
Cell Therapy$2.82M · 1.7%
Agricultural Biology$2.18M · 1.3%
Geographic
$85.39M totalNorth America$41.23M · 48.3%
Asia Pacific$35.22M · 41.2%
Europe$8.94M · 10.5%
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-1.23
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Laboratory Analytical Instruments
Comparing Bruker Cellular Analysis against the 5 most active filers in the same SIC group.